Receive our newsletter – data, insights and analysis delivered to you
June 18, 2009

AMT Pancreatitis Drug Shows Benefits After One Administration

Dutch biopharmaceutical company Amsterdam Molecular Therapeutics' (AMT) lead product, Glybera, has demonstrated long-term health benefits in one-time administration for patients with acute pancreatitis. Three-year follow-up data for the eight patients in the first clinical trial showed a

By cms admin

Dutch biopharmaceutical company Amsterdam Molecular Therapeutics’ (AMT) lead product, Glybera, has demonstrated long-term health benefits in one-time administration for patients with acute pancreatitis.

Three-year follow-up data for the eight patients in the first clinical trial showed a statistically significant, ten-fold decrease in the incidence of acute pancreatitis.

From the second trial in 14 patients, one-year data is already showing similar results.

The data from both trials also confirm that the treatment is well tolerated and safe.

Related Companies

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU